Innate Pharma (IPHA) Profit After Tax (2019 - 2025)

Innate Pharma (IPHA) has reported Profit After Tax for 7 consecutive years, with -$56.0 million the latest figure, recorded in Q4 2025.

• Quarterly Profit After Tax rose 0.59% year-over-year to -$56.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (up 34.65% YoY) and the FY2025 annual result came in at -$56.0 million, up 0.59% from the prior year.
• Profit After Tax slipped to -$56.0 million in Q4 2025 per IPHA's latest filing, from $48.6 million in the prior quarter.
• Over the last five years, Profit After Tax for IPHA reached as high as $56.4 million in Q2 2024 and fell as low as -$66.1 million in Q4 2022.
• A 5-year average of -$10.1 million and a median of -$8.6 million in 2023 frame the typical range for Profit After Tax.
• The largest YoY upside for Profit After Tax was 2225.67% in 2024 against a maximum downside of 553.51% in 2024.
• Year by year, Profit After Tax stood at -$60.1 million in 2021, then decreased by 10.02% to -$66.1 million in 2022, then soared by 86.97% to -$8.6 million in 2023, then slumped by 553.51% to -$56.3 million in 2024, then climbed by 0.59% to -$56.0 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$56.0 million, $48.6 million, and -$56.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.